Organon Acquired by Sun Pharmaceutical Industries | Healthcare M&A Deal

Sun Pharmaceutical Industries has acquired Organon, a women’s health pharmaceuticals business in India, for $11.75 billion. Organon is a dedicated women’s health pharma company with a portfolio of more than 70 products across reproductive health, fertility, pregnancy, menopause, and general medicines, commercialized across about 140 countries. The Sun Pharmaceutical Industries acquisitions strategy targets Organon’s global reach and biosimilars capabilities to build a larger women’s health commercial platform. The merger acquisition is an all-cash strategic acquisition by a strategic buyer and is expected to close in early 2027, with Organon stockholders receiving $14.00 per share.